VJHemOnc is committed to improving our service to you

EBMT 2020 | Narsoplimab for TA-TMA

VJHemOnc is committed to improving our service to you

Eleni Gavriilaki

Eleni Gavriilaki, MD, PhD, George Papanicolaou Hospital, Thessaloniki, Greece, discusses the use of narsoplimab, a monoclonal antibody targetting mannan-binding lectin serine protease 2 (MASP-2), for the treatment of transplant-associated thrombotic microangiopathy (TA-TMA), an endothelial damage syndrome that’s increasingly found as a complication of autologous and allogeneic hematopoietic cell transplantation. This interview was recorded via an online conference call with The Video Journal of Hematological Oncology (VJHemOnc).

Share this video  
Similar topics

Sign-up for our Newsletter!

Keep up to date with all the latest news with our monthly newsletter